Update on the Management and Therapeutic Monitoring of Advanced Nasopharyngeal Cancer
- 1 December 2008
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 22 (6) , 1267-1278
- https://doi.org/10.1016/j.hoc.2008.08.012
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- The impact of18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosisThe British Journal of Radiology, 2008
- Nasopharyngectomy for recurrent nasopharyngeal carcinoma: a review of 53 patients and prognostic factorsActa Oto-Laryngologica, 2008
- Prospective Randomized Study of Intensity-Modulated Radiotherapy on Salivary Gland Function in Early-Stage Nasopharyngeal Carcinoma PatientsJournal of Clinical Oncology, 2007
- 18F-FDG PET Can Replace Conventional Work-up in Primary M Staging of Nonkeratinizing Nasopharyngeal CarcinomaJournal of Nuclear Medicine, 2007
- Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2006
- Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaJournal of Clinical Oncology, 2005
- Long-Term Survival After Cisplatin-Based Induction Chemotherapy and Radiotherapy for Nasopharyngeal Carcinoma: A Pooled Data Analysis of Two Phase III TrialsJournal of Clinical Oncology, 2005
- Concurrent and Adjuvant Chemotherapy for Nasopharyngeal Carcinoma: A Factorial StudyJournal of Clinical Oncology, 2004
- Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20‐year period (1980–99): An encouraging reduction in both incidence and mortalityInternational Journal of Cancer, 2002
- Plasma Epstein-Barr Virus DNA and Residual Disease After Radiotherapy for Undifferentiated Nasopharyngeal CarcinomaJNCI Journal of the National Cancer Institute, 2002